| Current Price | $1.20 | Mkt Cap | $33.16M |
|---|---|---|---|
| Open | $0.00 | P/E Ratio | 0.00 |
| Prev. Close | $1.16 | Div. (Yield) | N/A (N/A) |
| Daily Range | $1.15 - $1.31 | Volume | 25,689 |
| 52-Wk Range | $0.95 - $3.10 | Avg. Daily Vol. | 0 |
News & Discussion Boards
- CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012 2/6/2012 10:23:00 AM -
- Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva® and Avastin® in Patients with Advanced Non-Small Cell Lung Cancer 1/20/2012 8:00:00 AM -
- Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck 1/9/2012 7:00:00 AM -
- Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO-4200, a Dual Agonist of TLRs 7 and 8, at the American Society for Hematology Meeting 12/13/2011 4:15:00 PM -
- Idera: FDA Orders Hold On Midstage Trial Of Psoriasis Treatment 7/20/2011 5:50:59 PM
- Idera Pharma Postpones Phase 2 Trial of Hepatitis C Treatment 4/22/2011 8:49:00 AM
| Subject | Recs | Author | Date |
|---|
